WTl-specific cytotoxic T lymphocytes (CTL), CD8+ lymphocytes or CD4+ lymphocytes, obtained by a method comprising contacting a lymphocyte cell population in vitro or ex vivo with one or more specific WT1 peptides, thereby inducing the formation and proliferation of the WT1-specific lymphocytes, for use in treating a subject with a WT1-expressing cancer or for use in reducing the incidence of a WT1-expressing cancer or its relapse.
